26 Landsdowne Street
3 articles with Beam Therapeutics
Beam Therapeutics Secures $135 Million in Series B Financing to Advance Base Editing Platform and Expand Pipeline of Precision Genetic Medicines
Beam Therapeutics today announced the successful completion of a $135 million Series B financing.
Beam Therapeutics is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.